echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > News: 144 varieties transferred out of medical insurance (list attached)

    News: 144 varieties transferred out of medical insurance (list attached)

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    144 varieties will be transferred out before August 1 next year at the latestaccording to the industry news, some drugs will be transferred out of the notice of Sichuan basic medical reimbursement, industrial injury insurance and maternity insurance drug catalogue (2018 version) (hereinafter referred to as the notice)< br / > the message shows that six kinds of invert sugar electrolyte injections included in the national key monitoring scope will be transferred out of the drug catalog from July 1, 202094 kinds of drugs such as domiphene lozenges were transferred out of the drug catalogue from August 1, 202044 kinds of drugs, such as aluminum magnesium aspirin (II), were transferred out of the drug catalogue on August 1, 2021The above drugs shall be paid in accordance with the relevant provisions of the drug catalog before being transferred out< br / > at the same time, all regions are required to attach great importance to it, strictly follow the transfer out varieties and time limit stipulated in this notice, and shall not change the transfer out varieties and time limit by themselves, so as to ensure the implementation of decision-making and deployment, among them, 6 kinds of drugs, including invert sugar electrolyte injection, including invert sugar electrolyte injection, thymus five peptide injection, brain glycoside carnosine injection, calf serum deproteinized injection, Danshen Chuan Qiong zine injection and Coenzyme Complex for Injection, these 6 drugs were transferred out of Sichuan medical insurance directory before July 1st< br / > in addition, 28 Western medicines including domiphene lozenges, pepsin oral constant release dosage form, aspirin suppository, anticoagulant No.1 injection for blood transfusion, compound three-dimensional ferrous oral liquid, including 52 Chinese patent medicines such as Banlangen chewable tablets, andrographolide tablets, Jiuwei antiviral granules, Yigan granules, xiaoerdingfeng pills, Chuanbei cough syrup, etc, As well as 14 drugs including compound enalapril tablets, rosiglitazone metformin maleate tablets and tetraforazine phosphate glucose injection, they are required to be transferred out of the medical insurance catalog before August 1in addition to the above 100 drugs to be transferred before 7-8 this year, Sichuan Province announced 44 varieties at the same time, relaxed the time of transfer, asked it to dial out the catalogue before August 1, 202144 drugs include aluminum magnesium aspirin (II), alendronate sodium and vitamin D3, doxofylline and glucose injection, roxithromycin and ambroxol dispersible tablets, calf spleen extract injection, ornithine aspartate granules, Potassium Aspartate Injection, etc< br / > it is worth noting that in December 2019, Sichuan Medical Security Bureau issued a document: provincial supplementary drugs, which have been included in the catalogue of drugs for national basic medical insurance, work injury insurance and maternity insurance, shall be implemented in accordance with the national regulations; those not included in the national drug catalogue shall be implemented temporarily in accordance with the original regulations and gradually digested within 3 years; the deleted varieties in the National Drug Catalogue shall not be implemented< br / > at the same time, Sichuan Medical Insurance Bureau also attached the list of deleted Western medicines and the list of deleted Chinese patent medicines in the national drug catalogThat is to say, 275 Western medicines and 71 Chinese patent medicines have been completely removed from the medical insurance catalogue of Sichuan Province, but the specific transfer out time and varieties have not been attached< br / > this time, Sichuan Province issued a document again, confirmed the varieties and time of three batches of transferred out directories, and further implemented the above documents< br / > in August 2019, the state health insurance bureau issued the notice of the Ministry of human resources and social security of the State Health Insurance Bureau on printing and distributing the catalogue of drugs for national basic medical insurance, work injury insurance and maternity insuranceIt is clear in the notice that class B drugs added according to regulations in the original provincial drug catalogue shall be gradually digested within 3 years < br / > in September, sepiland confirmed from authoritative channels that the arrangements for local supplementary varieties to be transferred out of the medical insurance are as follows: < br / > 1 Drugs in the key monitoring directory will be moved out of the medical insurance directory first; < br / > 2 In principle, other local supplementary varieties will be cleaned up within three years, with the proportion of varieties cleaned up in three years being 40%, 40% and 20%, respectively < br / > it is understood that although at least 15 provinces and cities, such as Jiangxi, Shandong, Beijing, Hunan, Sichuan, Guangdong, Tianjin, Zhejiang, Anhui, Guangxi and so on, have eliminated and clearly issued the supplementary catalogue of local medical insurance catalogue, most provinces and cities have only published the product catalogue of the medical insurance catalogue transferred out in 2019, without specifically indicating the transfer out time of the corresponding varieties < br / > therefore, Chongqing and Sichuan have certain benchmarking and demonstration significance < br / > on June 8, Chongqing Medical Insurance Bureau issued the announcement on the list of gradually digesting the local supplement of Medicare B drugs in Chongqing, and released the three-year digesting principle and the proposed list of three-year digesting drugs for local supplement of Medicare B drugs < br / > according to the statistics of Fengyun pharmaceutical, 405 products of provincial increased medical insurance will be eliminated in three years in Chongqing; 193 products will be eliminated in 2020, accounting for 48%; 118 products will be eliminated in 2021, accounting for 29%; 93 products will be eliminated in 2022, accounting for 23% According to Zhang Tingjie, the so-called "4:4:2" of the state is the bottom line of the elimination of provincial increase in health insurance, rather than the strict proportion For example, Chongqing is the 5:3:2 ratio; other provinces, especially those with relatively tight health insurance funds, may be more eliminated in addition to Chongqing, Sichuan also made clear the three batch of drug elimination time, the fastest two batches in July 1st and August 1st before the transfer of health insurance directory, the slowest also need to be transferred before August 1st next year, the rhythm is very fast, so leaving the window for pharmaceutical companies is also very short < br / > according to the information conveyed by the state health insurance bureau at the relevant meeting, the drugs in the key monitoring directory are the first to be removed from the health insurance directory, which is no doubt In addition, Xiong Xianjun, director of the medical service management department of the State Medical Insurance Bureau, said: "from the perspective of the varieties transferred out, some of them have relatively large annual sales volume To transfer such drugs out of the catalog is conducive to making room for more good drugs for life-saving and emergency rescue, as well as accelerating the transformation and upgrading of the industry." < br / > for the varieties that want to save the country by adding the local medical insurance catalog, because this round of adjustment failed to enter the national medical insurance, although the last round of adjustment entered the local medical insurance, this method also basically failed At present, the specific list of three batches of digestive drugs in Chongqing and Sichuan Province conforms to these two characteristics < br / > now more and more provinces begin to take action Chongqing and Sichuan Province, which have given clear practices, may give some reference to the provinces that have not listed in the future < br / > a person in the industry once said to saberland: provinces have given pharmaceutical enterprises and medical institutions a three-year buffer period, which is to consider the stability of enterprises, platforms and agents, patient compliance and other factors; at the same time, they have also given industrial transformation opportunities The purpose of the three years is to give out opportunities to come in again, such as those in line with the standards of basic drug catalog and evidence-based medicine, A drug that proves clinical efficacy The goal of national reform is to let the health insurance fund be used on the cutting edge, not to kill some enterprises < br / > in the future, the manufacturers involved in these varieties should seize the window period and reconsider the market strategy
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.